Clinical Pharmacokinetics and Pharmacodynamics of the Cyclin-Dependent Kinase 4 and 6 Inhibitors Palbociclib, Ribociclib, and Abemaciclib
出版年份 2020 全文链接
标题
Clinical Pharmacokinetics and Pharmacodynamics of the Cyclin-Dependent Kinase 4 and 6 Inhibitors Palbociclib, Ribociclib, and Abemaciclib
作者
关键词
-
出版物
CLINICAL PHARMACOKINETICS
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2020-10-08
DOI
10.1007/s40262-020-00930-x
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Pharmacokinetic Targets for Therapeutic Drug Monitoring of Small Molecule Kinase Inhibitors in Pediatric Oncology
- (2020) Julie M. Janssen et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Predicting Clinical Effects of CYP3A4 Modulators on Abemaciclib and Active Metabolites Exposure Using Physiologically Based Pharmacokinetic Modeling
- (2020) Maria M. Posada et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Use of the Child-Pugh score in anticancer drug dosing decision making: proceed with caution
- (2019) Carlo Palmieri et al. LANCET ONCOLOGY
- P-glycoprotein Limits Ribociclib Brain Exposure and CYP3A4 Restricts Its Oral Bioavailability
- (2019) Alejandra Martínez-Chávez et al. MOLECULAR PHARMACEUTICS
- Association between ribociclib and changes in creatinine in patients with hormone receptor positive metastatic breast cancer
- (2019) Brooke E. Wilson et al. INTERNAL MEDICINE JOURNAL
- Prediction of pH-Dependent Drug-Drug Interactions for Basic Drugs using Physiologically based Biopharmaceutics Modeling: Industry Case Studies
- (2019) Amitava Mitra et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer
- (2019) Dennis J. Slamon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer
- (2018) G N Hortobagyi et al. ANNALS OF ONCOLOGY
- Ribociclib shows potential for pharmacokinetic drug-drug interactions being a substrate of ABCB1 and potent inhibitor of ABCB1, ABCG2 and CYP450 isoforms in vitro
- (2018) Ales Sorf et al. BIOCHEMICAL PHARMACOLOGY
- Feasibility and acceptability of combining cognitive behavioural therapy techniques with swallowing therapy in head and neck cancer dysphagia
- (2018) J. M. Patterson et al. BMC CANCER
- Abstract P5-21-21: Palbociclib exposure-response analyses in the treatment of hormone-receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2–) advanced breast cancer (ABC)
- (2018) J Zheng et al. CANCER RESEARCH
- Abstract P1-10-14: Abemaciclib tablet formulation is bioequivalent to capsules
- (2018) PK Turner et al. CANCER RESEARCH
- Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: MONALEESA-3
- (2018) Dennis J. Slamon et al. JOURNAL OF CLINICAL ONCOLOGY
- Harnessing soft tissue sarcoma with low-dose pazopanib – a matter of blood levels
- (2018) Stefanie L. Groenland et al. BMC CANCER
- Abemaciclib inhibits renal tubular secretion without changing glomerular filtration rate
- (2018) Jill C. Chappell et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Palbociclib in combination with letrozole in patients with estrogen receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: PALOMA-2 subgroup analysis of Japanese patients
- (2018) Hirofumi Mukai et al. International Journal of Clinical Oncology
- Palbociclib in combination with fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-3 subgroup analysis of Japanese patients
- (2018) Norikazu Masuda et al. International Journal of Clinical Oncology
- MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
- (2017) George W. Sledge et al. JOURNAL OF CLINICAL ONCOLOGY
- MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
- (2017) Matthew P. Goetz et al. JOURNAL OF CLINICAL ONCOLOGY
- Characterization of Neutropenia in Advanced Cancer Patients Following Palbociclib Treatment Using a Population Pharmacokinetic-Pharmacodynamic Modeling and Simulation Approach
- (2017) Wan Sun et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study
- (2016) G. Curigliano et al. BREAST
- Phase 1 study of abemaciclib, an inhibitor of CDK 4 and 6, as a single agent for Japanese patients with advanced cancer
- (2016) Yutaka Fujiwara et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Abstract CT152: Food effect on the pharmacokinetics of 200-mg abemaciclib in healthy subject: Table 1
- (2016) Kellie Turner et al. CANCER RESEARCH
- Abstract LB-196: A phase I open-label, fixed-sequence, two-period crossover study of the effect of multiple doses of Itraconazole on Palbociclib (PD–0332991) pharmacokinetics in healthy volunteers
- (2016) Justin T. Hoffman et al. CANCER RESEARCH
- Abstract LB-198: A phase I open-label fixed-sequence two-period crossover study of the effect of multiple doses of modafinil on palbociclib (PD–0332991) pharmacokinetics in healthy volunteers
- (2016) Justin T. Hoffman et al. CANCER RESEARCH
- Phase I study of palbociclib, a cyclin-dependent kinase 4/6 inhibitor, in Japanese patients
- (2016) Kenji Tamura et al. CANCER SCIENCE
- A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas
- (2016) J. R. Infante et al. CLINICAL CANCER RESEARCH
- Physiologically Based Pharmacokinetic Modeling of Palbociclib
- (2016) Yanke Yu et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance
- (2016) P. Chen et al. MOLECULAR CANCER THERAPEUTICS
- Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
- (2016) Gabriel N. Hortobagyi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Palbociclib and Letrozole in Advanced Breast Cancer
- (2016) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors
- (2016) A. Patnaik et al. Cancer Discovery
- Abstract 4515: A phase 1 randomized, open-label, fixed-sequence, 2-period study of the effect of multiple doses of rifampin on palbociclib (PD-0332991) pharmacokinetics in healthy volunteers
- (2015) Justin T. Hoffman et al. CANCER RESEARCH
- P-glycoprotein and breast cancer resistance protein restrict the brain penetration of the CDK4/6 inhibitor palbociclib
- (2015) Mark C. de Gooijer et al. INVESTIGATIONAL NEW DRUGS
- Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
- (2015) Nicholas C. Turner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mitigation of acute kidney injury by cell-cycle inhibitors that suppress both CDK4/6 and OCT2 functions
- (2015) Navjotsingh Pabla et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Abstract CT419: A phase 1 randomized, open-label, 2-sequence, 2-period crossover study of the effect of multiple doses of palbociclib (PD-0332991) on midazolam pharmacokinetics in healthy women of non-childbearing potential
- (2015) Justin T. Hoffman et al. CANCER RESEARCH
- Semi-Mechanistic Pharmacokinetic/Pharmacodynamic Modeling of the Antitumor Activity of LY2835219, a New Cyclin-Dependent Kinase 4/6 Inhibitor, in Mice Bearing Human Tumor Xenografts
- (2014) S. C. Tate et al. CLINICAL CANCER RESEARCH
- Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine
- (2014) Lawrence M. Gelbert et al. INVESTIGATIONAL NEW DRUGS
- Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1)
- (2011) G K Schwartz et al. BRITISH JOURNAL OF CANCER
- Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer
- (2011) K. T. Flaherty et al. CLINICAL CANCER RESEARCH
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started